Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc has announced successful completion of their first cohort and initiated dosing in the second cohort of their AVA6000 Phase 1 trial, which includes a FAPI-PET sub-study to enhance tumor targeting. The trial evaluates AVA6000, leveraging their pre|CISION™ technology to deliver doxorubicin chemotherapy with improved safety. The company remains on track with their goals for the second half of 2024, anticipating the commencement of a Phase 1b efficacy study and further data presentations.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
